News
The day at a glance · 4 min read
Mood · Risk-On
+65
Sentiment, −100 to +100
LLY Dividend Growth
15.17%
Healthcare Market Overview
LLY Payout Ratio
22%
Healthcare Market Overview
ABBV Price Target
$298
Big Pharma & Biotech
Key driverNext-generation vaccine candidates, expanded pipeline franchises, and medical device innovation are driving optimism across large-cap pharma and biotech
Daily briefHealthcare· Money365.Market AI ·

Pharma Giants Advance Pipelines; Berkshire Exits UNH

Pipeline updates from Pfizer, AbbVie, and Amgen highlight innovation momentum as J&J unveils coronary device and Berkshire dumps UnitedHealth stake

Healthcare Market Overview

Bullish
LLYAMGNABBV
The healthcare sector is experiencing a wave of pipeline advancements and strategic collaborations as large-cap pharmaceutical companies push next-generation therapies toward commercialization.
JPMorgan has described the biotech sector as being at a critical inflection point as pipeline successes increasingly translate into profitable commercial franchises, resuming coverage on 14 large-cap biotechnology companies.
Eli Lilly ($LLY) continues to demonstrate strong fundamentals with a 15.17% annual dividend increase and a 22% payout ratio, supported by exceptional profitability and explosive earnings growth. The longevity industry is booming with high-tech tests, drugs, and medical devices, with $LLY positioned as a key player in weight loss drugs and broader therapeutic innovation.

Big Pharma & Biotech

Bullish

AMGN Price Target

$427
PFEABBVAMGN
Pfizer ($PFE) reported positive Phase 2 results for its investigational 25-valent pneumococcal conjugate vaccine in infants, showing strong immune responses versus PREVNAR 20 and prompting the launch of a pivotal Phase 3 pediatric program. The company is aiming to extend its long-standing pneumococcal franchise through higher-value, next-generation products, including plans for a fifth-generation 35-valent adult vaccine.
$PFE and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the first FDA approved oral PROTAC for advanced breast cancer, introducing a new commercialization pathway and partnership-driven revenue channel.
AbbVie ($ABBV) received an Overweight rating from Piper Sandler, which raised its price target to $298 from $294, buoyed by the company's inflammatory bowel disease pipeline as management moves forward with Skyrizi in combination therapies.
Amgen ($AMGN) received an Overweight rating from Piper Sandler with a lowered price target to $427 from $432, though the new target still represents significant upside potential as the firm expects the company to deliver top-line revenue growth.

MedTech & Devices

Bullish

Coronary Disease Patients

315 million

TMO Quarterly Dividend

$0.47
JNJTMO
Johnson & Johnson ($JNJ) reaffirmed its push for opportunities in the treatment of calcified coronary artery disease, which affects about 315 million people worldwide. The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation intravascular lithotripsy catheter designed to address this significant patient population.
$JNJ is one of Navellier's top long-term stock picks, supported by this medical device innovation and the company's diversified healthcare portfolio.
Thermo Fisher Scientific ($TMO) announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026.

FDA & Regulation

Bullish
PFEMRK
Pfizer ($PFE) and its partners have received FDA approval for VEPPANU (vepdegestrant), the first FDA approved oral PROTAC for advanced breast cancer, following Phase 3 data that support clinical benefit in a difficult to treat patient group. The agreement with Rigel Pharmaceuticals follows inclusion of VEPPANU in NCCN breast cancer guidelines, validating the therapy's clinical utility.
Exelixis is collaborating with Merck ($MRK) to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx as the companies pursue late-stage development in oncology.

Health Insurance & Managed Care

Bearish
UNH
UnitedHealth ($UNH) experienced a stock slide after Berkshire Hathaway, under Greg Abel's direction, dumped its entire stake in the managed care giant. Despite the near-term selling pressure triggered by Berkshire's exit, analysts suggest the real story for long-term investors is far more encouraging, pointing to the company's fundamental strength in the health insurance and managed care space. The divestiture represents a significant shift in Berkshire's healthcare portfolio positioning.

Strategic Collaborations

Bullish

Nvidia Biotech Investment

$10.4 million

Roivant Moderna Settlement

$2.25 billion
GILDMRNA
Gilead Sciences ($GILD) announced a renewed five-year collaboration with the World Health Organization, committing funding, strategic support and product donations to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. VL is the second deadliest parasitic disease after malaria and is a sandfly-borne illness that attacks internal organs and can be fatal if untreated. An AI biotech stock landed a $10.4 million Nvidia investment, highlighting growing confidence in AI-powered biotech stocks as technology companies expand their healthcare technology investments.
Roivant Sciences strengthened its financial position with a $2.25 billion Moderna settlement and is preparing for key drug launches amidst mixed study results.

Looking Ahead

Bullish
PFEMRKABBV
The biotech sector stands at an inflection point with multiple large-cap companies advancing late-stage pipeline candidates toward commercialization and regulatory milestones.
Pfizer ($PFE) is launching its pivotal Phase 3 pediatric pneumococcal vaccine program following positive Phase 2 data, positioning the company for potential market expansion in the coming quarters.
Exelixis and Merck ($MRK) are advancing their phase III colorectal cancer study with zanzalintinib, representing a key catalyst for both companies' oncology franchises. Investors should monitor upcoming clinical trial readouts and regulatory decisions as pharmaceutical companies translate pipeline strength into revenue growth.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy